Why This Late-Stage Kidney Cancer Study Could Be Huge

By Chris Lange Published Apr 20, 9:47AM EDT

Follow 24/7 Wall St. on Google

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

Why This Late-Stage Kidney Cancer Study Could Be Huge — © Thinkstock

Exelixis Inc. (NASDAQ: EXEL | EXEL Price Prediction) stock jumped early on Monday after the company, in conjunction with Bristol-Myers Squibb Co. (NYSE: BMY), announced positive late-stage results from its kidney cancer study.

Specifically, the results come from the pivotal Phase 3 CheckMate-9ER trial evaluating Opdivo in combination with Cabometyx compared to sunitinib in previously untreated advanced or metastatic renal cell carcinoma (RCC).

The study met its primary endpoint of progression-free survival at final analysis, as well as the secondary endpoints of overall survival at a pre-specified interim analysis, and objective response rate.

Some quick background: RCC is the most common type of kidney cancer in adults, accounting for more than 140,000 deaths worldwide each year. RCC is approximately twice as common in men as in women, with the highest rates of the disease in North America and Europe.

Dr. Toni Choueiri, director of the Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute, and Jerome and Nancy Kohlberg, Professors of Medicine at Harvard Medical School, commented:

The results from the pivotal CheckMate -9ER trial clearly demonstrate the combination of cabozantinib plus nivolumab provides a clinically meaningful benefit in the key efficacy measures of progression-free survival and overall survival for previously untreated kidney cancer patients. Preliminary assessment of the data shows the combination of a 40mg dose of cabozantinib plus nivolumab demonstrated a favorable safety profile. If approved, this combination may become an important new first-line option for patients with metastatic renal cell carcinoma. We look forward to presenting detailed results at an upcoming congress.

[nativounit]

Exelixis stock traded up almost 21% at $23.50 early Monday, in a 52-week range of $13.67 to $23.00. The consensus price target is $24.46.

Bristol-Myers Squibb stock traded at $62.08 and has a 52-week range of $42.48 to $68.34. The consensus price target is $70.45.

[recirclink id=683182][wallst_email_signup]

About the Author Chris Lange →

Chris Lange is a writer for 24/7 Wall St., based in Houston. He has covered financial markets over the past decade with an emphasis on healthcare, tech, and IPOs. During this time, he has published thousands of articles with insightful analysis across these complex fields. Currently, Lange's focus is on military and geopolitical topics.

Lange's work has been quoted or mentioned in Forbes, The New York Times, Business Insider, USA Today, MSN, Yahoo, The Verge, Vice, The Intelligencer, Quartz, Nasdaq, The Motley Fool, Fox Business, International Business Times, The Street, Seeking Alpha, Barron’s, Benzinga, and many other major publications.

A graduate of Southwestern University in Georgetown, Texas, Lange majored in business with a particular focus on investments. He has previous experience in the banking industry and startups.